Trial Profile
Lorlatinib neurocognitive adverse events: how to improve patient care
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2018
Price :
$35
*
At a glance
- Drugs Lorlatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms lorlatinib neurocognitief
- 14 Nov 2018 New trial record